Please use this identifier to cite or link to this item:
Title: Efficacy and safety of Pegylated Interferon-α2b Plus Ribavirin for the treatment of chronic hepatitis C in HIV-infected patients
Author: Santín Cerezales, Miguel
Shaw Perujo, Evelyn
Garcia, M. Jose
Delejido, Antonio
Rodriguez De Castro, Eduardo
Rota, Rosa
Altés, Jordi
Baguena, Francisco
Valero, Silvia
Sala, Montserrat
Casanova Rituerto, Aurora
HCV/HIV-01 Study Team
Keywords: Interferó
Efecte dels medicaments sobre els microorganismes
Medicaments antivírics
Infeccions per VIH
Hepatitis C
Effect of drugs on microorganisms
Antiviral agents
HIV infections
Hepatitis C
Issue Date: 19-Apr-2006
Publisher: Mary Ann Liebert
Abstract: Low response rates and concerns about safety have limited the implementation of treatment for chronic hepatitis C (CHC) in patients with HIV infection. The efficacy and safety of pegylated interferon (peg-IFN) plus ribavirin in HIV-infected patients with CHC were evaluated in a prospective, open-label, multicenter study. Sixty patients with persistently high transaminases, positive HCV-RNA, CD4 count ≥300 cells/µl, and HIVRNA <10,000 copies/ml were included. Patients were given peg-IFN 80-150 µg/week plus ribavirin 800-1200 mg/day. Treatment was scheduled for 24 weeks for genotypes 2/3 and 48 weeks for genotypes 1/4. In an intent- to-treat analysis, 16 (26.7%) patients achieved a sustained virological response (SVR). Twenty patients (33.3%) discontinued treatment prematurely, but only in 10 (16.6%) was discontinuation due to adverse events. Negative predictive values for SVR on the basis of HCV-RNA decline between baseline and week 4 were 100% for 1- and 2-log10 fall, and positive predictive values were 40% and 58.3% for 1- and 2-log10 fall, respectively. CD4 fell by a median of 216 cells during treatment, but no HIV-associated complications occurred. In conclusion, treatment with peg-IFN alfa-2b plus ribavirin is safe and clears RNA-HCV in about one-quarter of HIV-infected patients with CHC. Efforts should be focused on optimizing management of side effects and counseling to improve adherence and to keep patients on treatment. Assessment of HCV-RNA at week 4 may help guide early therapeutic decision making.
Note: Reproducció del document publicat a:
It is part of: Aids Research and Human Retroviruses, 2006, vol. 22, num. 4, p. 315-320
ISSN: 0889-2229
Appears in Collections:Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
544486.pdf81.16 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.